Amy S. Paller, MD - Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing T

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024.Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted TreatmentAtopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD.ChairAmy S. Paller, MDNorthwestern University Feinberg School of MedicineChicago, IllinoisPatient AdvocateKacey Jenkins In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy S. Paller, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc.Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc.Patient Advocate/PlannerKacey Jenkins has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.